# Bird Goën & Co C.V.B.A.

William Bird, MA (Cambridge), C.Eng. (1)(2)(3)(4)(5)
Ariane Bird (Goën) (1)(8)
Electronics, Physics, Telecommunications
Kris Hertoghe (1)(7)
Electronics, Mechanics, Physics
Thierry Dubost (1)(2)(6)
Chemistry, Biochemistry, Pharmaceuticals
Liesbet Paemen, Ph.D. (1)
Life Sciences, Biotechnology, Biomedics
Michel Marchau (1)(7)(9)
Electronics, Physics, Telecommunications
Wim Van Steenlandt (7)
Mechanics, Electromechanics, Fibres
Ivo De Baere, Ph.D.
Biotechnology, Life Sciences
An De Vrieze
Semiconductor Processing, Chemistry
Davy Wauters, Ph.D.
Physics, Optics
Birgit Verbeure, Ph.D.
Pharmaceuticals, Chemistry, Biochemistry
Christophe Ego, Ph.D.
Chemistry
Hannes Iserentant, Ph.D.
Life Sciences, Biology, Biomedical Sciences
consultant
Peter N. Cutforth, MA Eng (Cambridge) (1)(2)(3)(4)
Telecommunications, Software, Electronics

Klein Dalenstraat 42A
3020 Winksele
Belgium

tel +32-16-480562
fax +32-16-480528
email 106113.713@
compuserve.com
www.birdgoen.com



European Patent (1) and Trademark (2) Attorney
Registered British Patent (3) and Trademark (4) Agent
Deutscher Patentassessor (5)
French Patent and Trademark Attorney (6)
Belgian Patent Attorney (7)
Ingénieur en Propriété Intellectuelle (CEIPI) (8)
Luxemburg Patent Attorney (9)

EUROPEAN PATENT OFFICE
International Preliminary Examining Authority
**Mr. D. Klein** (Examiner)
Erhardtstrasse 27
D-80469 München
Duitsland

FAX 00 49 89 2399 4465 + confirmation

Winksele, March 20, 2006

Re: International patent application PCT/BE2005/000032
Filing date: 4 March 2005
Applicant: K.U.Leuven Research & Development
Title: "Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production"
Our ref: K3234-PCT/wb/td/kd

---

Dear Mr. Klein,

With reference to your telephone call on March 15, 2006, for which we thank you, we herewith file without prejudice a set of amended claims 1-13 wherein the word "isomers" has been replaced with "stereoisomers". Only the following claims have been amended:

- claim 1 at page 3, line 22,
- claim 2 at page 7, line 11,
- claim 3 at page 9, line 11; and
- claim 7 at page 12, line 29,

whereas claims 4-6 and 8-13 remain unchanged. Support for the amendment is to be found at pages 15 and 17 of the description as originally filed.

We look forward to receiving the International Preliminary Report on Patentability.

Very truly yours,

William E Bird

encl.:
- amended claims 1-13 (14 pages) (in triplicate)

## CLAIMS

1. A compound including a heterocyclic nucleobase attached to a first carbon atom of an optionally substituted five-member saturated or mono-unsaturated heterocyclic group selected from tetrahydrofuranyl, tetrahydrothienyl, dihydrofuranyl and dihydrothienyl and further including a phosphonoalkoxy or phosphonothioalkyl group attached to a second carbon atom of said five-member saturated or mono-unsturated heterocyclic group, said first carbon atom being adjacent to the heteroatom of said five-member saturated or mono-unsturated heterocyclic group, and said second carbon atom being adjacent neither to the heteroatom nor to the first carbon atom of said five-member saturated or mono-unsturated heterocyclic group, said compound being represented by one of the general formulae (II) and (XIX):



(II), and



(XIX)

wherein:

- $X^1$, $X^2$, $X^3$, $X^4$ and $X^5$ are each each independently selected from the group consisting of oxygen and sulfur,
- B is a natural or non-natural heterocyclic nucleobase,

- $R^1$ and $R^2$ are each independently selected from the group consisting of hydrogen; $(-PO_3R^{16})_m-PO_3R^{17}R^{18}$; alkyl; alkenyl; alkynyl; cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; arylalkyl; heterocyclic; heterocyclic-alkyl; acyloxyalkyl; acyloxyalkenyl; acyloxyalkynyl; acyloxyaryl; acyloxyarylalkyl; acyloxyarylalkenyl; acyloxyarylalkynyl; dialkylcarbonate; alkylarylcarbonate; alkylalkenylcarbonate; alkylalkynylcarbonate; alkenylarylcarbonate; alkynyl-arylcarbonate; alkenylalkynylcarbonate; dialkenylcarbonate; dialkynyl-carbonate; wherein said alkyl, alkenyl and alkynyl optionally contains one or more heteroatoms in or at the end of the hydrocarbon chain, said heteroatoms being independently selected from the group consisting of oxygen, sulfur and nitrogen;
- $R^3$, $R^4$, $R^5$, $R^6$, $R^7$ and $R^8$ are each independently selected from the group consisting of hydrogen, azido, halogen, cyano, alkyl, alkenyl, alkynyl, $SR^{14}$ and $OR^{14}$;
- $R^{14}$ is selected from hydrogen; alkyl; alkenyl; alkynyl; cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; heterocyclic; arylalkyl; heterocyclic-alkyl; acyloxyalkyl; wherein said alkyl, alkenyl and alkynyl optionally contain one or more heteroatoms in or at the end of the hydrocarbon chain, said heteroatoms being independently selected from the group consisting of oxygen, sulfur and nitrogen;
- $R^{16}$, $R^{17}$ and $R^{18}$ are independently selected from the group consisting of hydrogen; alkyl; alkenyl; alkynyl; cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; arylalkyl; heterocyclic ring; heterocyclic ring-alkyl; acyloxyalkyl; wherein said alkyl, alkenyl and alkynyl optionally contain one or more heteroatoms in or at the end of the hydrocarbon chain, said heteroatoms being independently selected from the group consisting of oxygen, sulfur and nitrogen;
- $X^4$ and $R^1$, or $X^5$ and $R^2$ may together form an amino-acid residue or polypeptide wherein a carboxyl function of said amino-acid residue being at a distance from the amidate nitrogen not further than 5 atoms is esterified;

- $X^4$ and $R^1$ or $X^5$ and $R^2$ may together form a group having the formula – $OC(R^9)_2OC(O)Y(R^{10})_a$ wherein Y = N or O, a = 1 when Y is O and a = 1 or 2 when Y is N;
- $R^9$ is selected from the group consisting of hydrogen, alkyl, aryl, alkenyl, alkynyl, alkenylaryl, alkynylaryl or alkylaryl, wherein each of said alkyl, alkenyl, alkynyl and aryl groups is optionally substituted with one or more atoms or groups selected from the group consisting of halo, cyano, azido, nitro and $OR^{14}$;
- $R^{10}$ is selected from the group consisting of hydrogen, alkyl, aryl, alkenyl, alkynyl, alkenylaryl, alkynylaryl and alkylaryl, wherein each of said alkyl, alkenyl, alkynyl and aryl groups is optionally substituted with one or more atoms or groups selected from the group consisting of halo, cyano, azido, nitro, $OR^{14}$ and $NR^{11}R^{12}$;
- $R^{11}$ and $R^{12}$ are each independently selected from the group consisting of hydrogen and alkyl, provided that at least one of $R^{11}$ and $R^{12}$ is not hydrogen;
- n is an integer representing the number of methylene groups between $X_2$ and P, each of said methylene groups being optionally and independently substituted with one or two substituents selected from the group consisting of halogen, hydroxyl, sulhydryl and $C_{1-4}$ alkyl, and n being selected from 1, 2, 3, 4, 5 and 6; and
- m is 0 or 1,

including pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof.

2. A compound according to claim 1, being represented by one of the general formulae (III) to (XVIII):



(III),



(IV),



(V),



(VI),



(VII),



(VIII),



(IX),



(X),



(XI),



(XII)



(XIII)



(XIV),



(XV),



(XVI)



(XVII), and



(XVIII)

wherein n, m, B, $X^1$, $X^2$, $X^3$, $X^4$, $X^5$, $R^1$, $R^2$, $R^3$, $R^4$, $R^5$, $R^6$, $R^7$, $R^8$, $R^9$, $R^{10}$, $R^{11}$, $R^{12}$, $R^{14}$, $R^{16}$, $R^{17}$ and $R^{18}$ are defined as in formula (II), including pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof.

3. A compound according to claim 1, being represented by any of the following formulae (XX) to (XXVI):



(XX),



(XXI),



(XXII),



(XXIII),



(XXIV),



(XXV), and



(XXVI),

wherein n, m, B, $X^1$, $X^2$, $X^3$, $X^4$, $X^5$, $R^1$, $R^2$, $R^3$, $R^4$, $R^7$, $R^8$, $R^9$, $R^{10}$, $R^{11}$, $R^{12}$, $R^{14}$, $R^{16}$, $R^{17}$ and $R^{18}$ are defined as in formula (II), including pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof.

4. A compound according to any of claims 1 to 3, wherein B is selected from the group consisting of hypoxanthine, guanine, adenine, cytosine, inosine, thymine, uracil, xanthine, 8-aza derivatives of 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine;

7-deaza-8-aza derivatives of adenine, guanine, 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 1-deaza derivatives of 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 7-deaza derivatives of 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 3-deaza derivatives of 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 6-azacytosine; 5-fluorocytosine; 5-chlorocytosine; 5-iodocytosine; 5-bromocytosine; 5-methylcytosine; 5-bromovinyluracil; 5-fluorouracil; 5-chlorouracil; 5-iodouracil; 5-bromouracil; 5-trifluoromethyluracil; 5-methoxymethyluracil; 5-ethynyluracil and 5-propynyluracil.

5. A compound represented by one of the following general formulae (XXXI) to (XXXVI):




(XXXI),




(XXXII),




(XXXIII),




(XXXIV),




(XXXV), and




(XXXVI),

wherein:

- U is an acyl group,
- V is a silyl group,
- W is an alkyl group,
- the snake-like symbol means any stereochemical arrangement of the respective bond,
- $B^p$ is an optionally protected heterocyclic nucleobase, and
- Phos is an O-protected phosphonoalkoxy group or phosphonothioalkyl group.

6. Use of a compound according to claim 5 as an intermediate for making a compound according to any of claims 1 to 4.

7. A compound according to any of claims 1 to 4, being selected from the group consisting of :

1-($N^6$-benzoyladenin-9-yl)-2-O-benzoyl-3-O-(diisopropylphosphonomethyl)-L-threose (**11**);

1-(thymin-1-yl)-2-O-benzoyl-3-O-(diisopropylphosphonomethyl)-L-threose(**12**);

1-(uracil-1-yl)-2-O-benzoyl-3-O-(diisopropylphosphonomethyl)-L-threose (**13**);

1-($N^4$-acetylcytosin-1-yl)-2-O-benzoyl-3-O-(diisopropylphosphonomethyl)-L-threose (**14**);

1-(adenin-9-yl)-3-O-(diisopropylphosphonomethyl)-L-threose (**15**);

1-(thymin-1-yl)-3-O-( diisopropylphosphonomethyl)-L-threose (**16**);

1-(uracil-1-yl)-3-O-( diisopropylphosphonomethyl)-L-threose (**17**);

1-(cytosin-1-yl)-3-O-(diisopropylphosphonomethyl )-L-threose (**18**);

1-(adenin-9-yl)-2-deoxy-3-O-(diisopropylphosphonomethyl)-L-threose (**19**);

1-(thymin-1-yl)-2-deoxy-3-O-(diisopropylphosphonomethyl)-L-threose (**20**);

1-(uracil-1-yl)-2-deoxy-3-O-(diisopropylphosphonomethyl)-L-threose (**21**);

1-(cytosin-1-yl)-2-deoxy-3-O-(diisopropylphosphonomethyl)-L-threose (**22**);

1-(adenin-9-yl)-3-O-(phosphonomethyl)-L-threose sodium salt (**3a**);

1-(thymin-1-yl)-3-O-(phosphonomethyl)-L-threose sodium salt (**3b**);

1-(uracil-1-yl)-3-O-(phosphonomethyl)-L-threose sodium salt (**3c**);

1-(cytosin-1-yl)-3-O-(phosphonomethyl)-L-threose sodium salt (**3d**);

1-(adenin-1-yl)-2-deoxy-3-O-(phosphonomethyl)-L-threose sodium salt (**3e**);

1-(thymin-1-yl)-2-deoxy-3-O-(phosphonomethyl)-L-threose sodium salt (**3f**);

1-(uracil-1-yl)-2-deoxy-3-O-(phosphonomethyl)-L-threose sodium salt (**3g**);

1-(cytidin-1-yl)-2-deoxy-3-O-(phosphonomethyl)-L-threose sodium salt (**3h**);

a pharmaceutically acceptable salt , an stereoisomer, a solvate or a pro-drug thereof.

7. The use of a compound according to any of the claims 1 to 4, for the manufacture of a medicament for the prevention or treatment of a viral infection in a mammal.

8. The use according to claim 7, wherein said viral infection is an infection by the Human Immunodeficiency Virus (HIV).

9. A pharmaceutical composition comprising a compound according to any of the claims 1 to 4 as an active ingredient in admixture with at least a pharmaceutically acceptable carrier.

10. A pharmaceutical composition according to claim 9, further comprising an antiviral agent.

11. A method of treatment or prevention of a viral infection in a mammal, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to any of claims 1 to 4.

12. A compound represented by one of the following general formulae (XXVIII) to (XXX):




(XXVIII),




(XXIX), and




(XXX),

wherein:

- U is an acyl group,
- V is a silyl group, and
- the snake-like symbol means any stereochemical arrangement of the respective bond.

13. Use of a compound according to claim 12 as an intermediate for making a compound according to any of claims 1 to 4.